{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.97","value":"67.0"},{"groupId":"OG001","spread":"22.08","value":"67.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.03","value":"52.4"},{"groupId":"OG001","spread":"26.10","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/quality of life (QOL) scale. The physical domain consisted of 5 items covering participant's daily physical activities on a scale from 1 (not at all) to 4 (very much). Raw scores were linearly transformed to a total score between 0-100, with a high score indicating better physical functioning.","dispersionType":"Standard Deviation","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEAN","populationDescription":"ITT PRO Population included participants with a measurement at study entry and at least one post study entry measurement for at least 1 subscale on all 3 questionnaires (EORTC QLQ-C30, EORTC Multiple Myeloma Module 20 \\[QLQ-MY20\\] and EuroQol 5-Dimensional Health Questionnaire \\[EQ-5D-5L\\]). Number analyzed are the number of participants with data available for analyses at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)","title":"Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Physical Domain Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}